Target intelligence / Profile preview

Inducible caspase-9 (iCasp9) (iCasp9)

Target
iCasp9
Molecular classification
Enzyme, Cysteine protease, Fusion protein, Safety switch, Suicide gene
01

Overview

The engineered ApoptiCIDe iCaspase-9 fusion is a synthetic safety switch designed to provide pharmacological control over cell and gene therapies. It consists of a modified human caspase-9 protein, lacking its endogenous caspase recruitment domain (CARD), fused to a mutated human FK506-binding protein (FKBP12-F36V) that serves as a dimerization domain. This fusion protein remains in an inactive monomeric state within the engineered cells until the administration of a small-molecule chemical inducer of dimerization (CID), such as rimiducid (AP1903). The CID cross-links the FKBP12 domains, bringing the caspase-9 molecules into close proximity to trigger their activation and the subsequent apoptotic death of the cells.

This technology is primarily utilized as a "kill switch" to mitigate severe treatment-related toxicities, such as cytokine release syndrome (CRS) or graft-versus-host disease (GvHD), in patients receiving chimeric antigen receptor (CAR) T-cell or stem cell therapies. By allowing for the rapid and selective elimination of the therapeutic cells, it enhances the safety profile of these advanced modalities. Recent developments by Phoenix SENOLYTIX have expanded the use of the ApoptiCIDe platform to in vivo gene therapies, where it is employed for the purposeful elimination of specific cell populations, such as senescent cells in aging-related disorders or adipocytes in obesity. The system is highly specific, as the dimerizer drugs are designed to be bio-inert and do not interact with endogenous proteins, minimizing off-target effects.

Other names
iC9CaspaCIDeApoptiCIDeInducible caspase-9 suicide geneCID-inducible caspase-9FKBP12-caspase-9 fusion protein
02

Mechanism of action

Small-molecule induced dimerization of the FKBP12-caspase-9 fusion protein, leading to the activation of the caspase-9 protease and subsequent initiation of the apoptotic cascade.

03

Biological functions

ApoptosisCell deathProteolysis
04

Disease associations

CancerGraft-versus-host diseaseAging-related disordersObesity
05

Safety considerations

Basal apoptosis (leakiness)Potential immunogenicity of the fusion proteinIncomplete elimination of target cellsInfusion reactions to dimerizer excipients
06

Interacting drugs

Rimiducid (AP1903)

2 more in the full profile.

07

Biomarkers

iCasp9 transgene expressionTruncated low-affinity nerve growth factor receptor (ΔNGFR)

Beyond the preview

Go deeper on Inducible caspase-9 (iCasp9) (iCasp9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inducible caspase-9 (iCasp9) (iCasp9).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call